EAM Investors LLC Invests $2.66 Million in Wave Life Sciences Ltd. (NASDAQ:WVE)

EAM Investors LLC bought a new position in Wave Life Sciences Ltd. (NASDAQ:WVE - Free Report) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor bought 214,717 shares of the company's stock, valued at approximately $2,656,000. EAM Investors LLC owned 0.14% of Wave Life Sciences at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of WVE. Barclays PLC increased its holdings in shares of Wave Life Sciences by 171.1% during the third quarter. Barclays PLC now owns 159,241 shares of the company's stock valued at $1,307,000 after acquiring an additional 100,498 shares in the last quarter. Geode Capital Management LLC raised its holdings in Wave Life Sciences by 14.3% in the third quarter. Geode Capital Management LLC now owns 2,269,664 shares of the company's stock worth $18,615,000 after buying an additional 283,419 shares during the last quarter. State Street Corp grew its holdings in shares of Wave Life Sciences by 2.6% during the third quarter. State Street Corp now owns 2,321,248 shares of the company's stock valued at $19,034,000 after buying an additional 57,822 shares during the last quarter. Moody Aldrich Partners LLC increased its position in shares of Wave Life Sciences by 31.5% during the fourth quarter. Moody Aldrich Partners LLC now owns 398,475 shares of the company's stock valued at $4,929,000 after acquiring an additional 95,413 shares in the last quarter. Finally, XTX Topco Ltd purchased a new position in Wave Life Sciences in the 3rd quarter worth approximately $126,000. 89.73% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

WVE has been the subject of several recent analyst reports. Jefferies Financial Group assumed coverage on Wave Life Sciences in a research note on Tuesday, February 25th. They issued a "buy" rating and a $26.00 price target for the company. HC Wainwright restated a "buy" rating and set a $22.00 target price on shares of Wave Life Sciences in a research note on Wednesday, March 26th. StockNews.com raised shares of Wave Life Sciences from a "sell" rating to a "hold" rating in a report on Saturday, March 8th. Finally, Wedbush assumed coverage on shares of Wave Life Sciences in a research report on Tuesday, April 8th. They issued an "outperform" rating and a $18.00 target price for the company. Two investment analysts have rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Wave Life Sciences has an average rating of "Moderate Buy" and an average price target of $22.18.

Insider Buying and Selling at Wave Life Sciences

In other Wave Life Sciences news, Director Christian O. Henry sold 10,500 shares of the stock in a transaction dated Thursday, March 20th. The shares were sold at an average price of $9.77, for a total transaction of $102,585.00. Following the completion of the transaction, the director now owns 16,115 shares of the company's stock, valued at $157,443.55. This represents a 39.45 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Paul Bolno sold 169,025 shares of the business's stock in a transaction dated Friday, March 7th. The stock was sold at an average price of $9.57, for a total value of $1,617,569.25. Following the completion of the sale, the chief executive officer now owns 338,351 shares in the company, valued at $3,238,019.07. This represents a 33.31 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 29.10% of the company's stock.

Wave Life Sciences Stock Up 4.7 %

WVE traded up $0.29 during midday trading on Tuesday, reaching $6.41. The company had a trading volume of 369,594 shares, compared to its average volume of 1,192,923. Wave Life Sciences Ltd. has a 1 year low of $4.25 and a 1 year high of $16.74. The company has a market cap of $983.85 million, a P/E ratio of -5.77 and a beta of -0.93. The business has a 50-day moving average of $8.82 and a two-hundred day moving average of $11.58.

Wave Life Sciences (NASDAQ:WVE - Get Free Report) last posted its quarterly earnings results on Tuesday, March 4th. The company reported $0.17 earnings per share for the quarter, topping analysts' consensus estimates of ($0.17) by $0.34. Wave Life Sciences had a negative net margin of 66.50% and a negative return on equity of 280.57%. The business had revenue of $83.75 million during the quarter, compared to analyst estimates of $25.60 million. On average, equities research analysts predict that Wave Life Sciences Ltd. will post -1.14 EPS for the current year.

Wave Life Sciences Profile

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.